The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia
While the impact of the timeliness of vaccine administration has been well-studied for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The aim of this study was to explore the impact of implementi...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2018-02, Vol.36 (10), p.1265-1271 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1271 |
|---|---|
| container_issue | 10 |
| container_start_page | 1265 |
| container_title | Vaccine |
| container_volume | 36 |
| creator | Chen, C. Wood, J.G. Beutels, P. Menzies, R. MacIntyre, C.R. Dirmesropian, S. Reyes, J.F. McIntyre, P. Newall, A.T. |
| description | While the impact of the timeliness of vaccine administration has been well-studied for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The aim of this study was to explore the impact of implementing more realistic observed uptake distributions, taking into the account reduced vaccine efficacy but higher pneumococcal disease burden with increasing age beyond 65 years. A multi-cohort Markov model was constructed to evaluate the cost-effectiveness of a pneumococcal (PCV13) immunisation program in Australia, assuming two different uptake modelling approaches. The approach using an estimate of observed uptake was compared with a scenario in which the total cumulative uptake was delivered at the recommended age of vaccination. We found these two approaches produced different results both in terms of cases prevented and cost-effectiveness. The impact of the non-timely uptake in adult programs may sometimes have positive and other times negative effects, depending on several factors including the age-specific disease rates and the duration of vaccine protection. Our study highlights the importance of using realistic assumptions around uptake (including non-timely vaccination) when estimating the impact of vaccination in adults. |
| doi_str_mv | 10.1016/j.vaccine.2018.01.052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1993993976</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X18301014</els_id><sourcerecordid>2001526573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-47ac801fa1038fc84d9badbad478cc2e3ab1bfe8f8299059df8479ba9ca504f73</originalsourceid><addsrcrecordid>eNqFkcuKFDEUhoMoTjv6CErAjZsqc6l0JW6kGbzBgJsR3IV06kRTpCptLg3zBj62abt14UY4kMX5_v-cnB-h55T0lNDt67k_Gmv9Cj0jVPaE9kSwB2hD5cg7Jqh8iDaEbYduoOTrFXqS80wIEZyqx-iKKa6E4MMG_bz7DjjFADg6XPwCoVnmjP2KS-vYmEsHzoEt_gi_O42LYYKEzVRDwectTPFxfYN32JoMOJc63Z_Awwp1iTZaa0LzWuf6zRS4aOA0ZFdzSSZ48xQ9ciZkeHZ5r9GX9-_ubj52t58_fLrZ3XaWK166YTRWEuoMJVw6K4dJ7c3UahiltQy42dO9A-kkU4oINTk5jA1R1ggyuJFfo1dn30OKPyrkohefLYRgVog1a6rabVqN24a-_AedY01r204zQqhgWzHyRokzZVPMOYHTh-QXk-41JfoUlZ715cP6FJUmVLeomu7Fxb3uF5j-qv5k04C3ZwDaOY4eks7Ww2ph8qnloafo_zPiFwuoqds</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2001526573</pqid></control><display><type>article</type><title>The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia</title><source>Elsevier ScienceDirect Journals</source><creator>Chen, C. ; Wood, J.G. ; Beutels, P. ; Menzies, R. ; MacIntyre, C.R. ; Dirmesropian, S. ; Reyes, J.F. ; McIntyre, P. ; Newall, A.T.</creator><creatorcontrib>Chen, C. ; Wood, J.G. ; Beutels, P. ; Menzies, R. ; MacIntyre, C.R. ; Dirmesropian, S. ; Reyes, J.F. ; McIntyre, P. ; Newall, A.T.</creatorcontrib><description>While the impact of the timeliness of vaccine administration has been well-studied for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The aim of this study was to explore the impact of implementing more realistic observed uptake distributions, taking into the account reduced vaccine efficacy but higher pneumococcal disease burden with increasing age beyond 65 years. A multi-cohort Markov model was constructed to evaluate the cost-effectiveness of a pneumococcal (PCV13) immunisation program in Australia, assuming two different uptake modelling approaches. The approach using an estimate of observed uptake was compared with a scenario in which the total cumulative uptake was delivered at the recommended age of vaccination. We found these two approaches produced different results both in terms of cases prevented and cost-effectiveness. The impact of the non-timely uptake in adult programs may sometimes have positive and other times negative effects, depending on several factors including the age-specific disease rates and the duration of vaccine protection. Our study highlights the importance of using realistic assumptions around uptake (including non-timely vaccination) when estimating the impact of vaccination in adults.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2018.01.052</identifier><identifier>PMID: 29395534</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult vaccination ; Adults ; Age ; Case reports ; Children ; Construction costs ; Cost analysis ; Disease ; Economic evaluation ; Elderly ; Expenditures ; Immunization ; Influenza ; Markov chains ; Multi-cohort Markov modelling ; Older people ; PCV13 ; Pharmaceuticals ; Pneumococcal ; Pneumonia ; Population ; Quantitative analysis ; Systematic review ; Timeliness ; Uptake ; Vaccination ; Vaccine efficacy ; Vaccines</subject><ispartof>Vaccine, 2018-02, Vol.36 (10), p.1265-1271</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 28, 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-47ac801fa1038fc84d9badbad478cc2e3ab1bfe8f8299059df8479ba9ca504f73</citedby><cites>FETCH-LOGICAL-c393t-47ac801fa1038fc84d9badbad478cc2e3ab1bfe8f8299059df8479ba9ca504f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X18301014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29395534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, C.</creatorcontrib><creatorcontrib>Wood, J.G.</creatorcontrib><creatorcontrib>Beutels, P.</creatorcontrib><creatorcontrib>Menzies, R.</creatorcontrib><creatorcontrib>MacIntyre, C.R.</creatorcontrib><creatorcontrib>Dirmesropian, S.</creatorcontrib><creatorcontrib>Reyes, J.F.</creatorcontrib><creatorcontrib>McIntyre, P.</creatorcontrib><creatorcontrib>Newall, A.T.</creatorcontrib><title>The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>While the impact of the timeliness of vaccine administration has been well-studied for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The aim of this study was to explore the impact of implementing more realistic observed uptake distributions, taking into the account reduced vaccine efficacy but higher pneumococcal disease burden with increasing age beyond 65 years. A multi-cohort Markov model was constructed to evaluate the cost-effectiveness of a pneumococcal (PCV13) immunisation program in Australia, assuming two different uptake modelling approaches. The approach using an estimate of observed uptake was compared with a scenario in which the total cumulative uptake was delivered at the recommended age of vaccination. We found these two approaches produced different results both in terms of cases prevented and cost-effectiveness. The impact of the non-timely uptake in adult programs may sometimes have positive and other times negative effects, depending on several factors including the age-specific disease rates and the duration of vaccine protection. Our study highlights the importance of using realistic assumptions around uptake (including non-timely vaccination) when estimating the impact of vaccination in adults.</description><subject>Adult vaccination</subject><subject>Adults</subject><subject>Age</subject><subject>Case reports</subject><subject>Children</subject><subject>Construction costs</subject><subject>Cost analysis</subject><subject>Disease</subject><subject>Economic evaluation</subject><subject>Elderly</subject><subject>Expenditures</subject><subject>Immunization</subject><subject>Influenza</subject><subject>Markov chains</subject><subject>Multi-cohort Markov modelling</subject><subject>Older people</subject><subject>PCV13</subject><subject>Pharmaceuticals</subject><subject>Pneumococcal</subject><subject>Pneumonia</subject><subject>Population</subject><subject>Quantitative analysis</subject><subject>Systematic review</subject><subject>Timeliness</subject><subject>Uptake</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkcuKFDEUhoMoTjv6CErAjZsqc6l0JW6kGbzBgJsR3IV06kRTpCptLg3zBj62abt14UY4kMX5_v-cnB-h55T0lNDt67k_Gmv9Cj0jVPaE9kSwB2hD5cg7Jqh8iDaEbYduoOTrFXqS80wIEZyqx-iKKa6E4MMG_bz7DjjFADg6XPwCoVnmjP2KS-vYmEsHzoEt_gi_O42LYYKEzVRDwectTPFxfYN32JoMOJc63Z_Awwp1iTZaa0LzWuf6zRS4aOA0ZFdzSSZ48xQ9ciZkeHZ5r9GX9-_ubj52t58_fLrZ3XaWK166YTRWEuoMJVw6K4dJ7c3UahiltQy42dO9A-kkU4oINTk5jA1R1ggyuJFfo1dn30OKPyrkohefLYRgVog1a6rabVqN24a-_AedY01r204zQqhgWzHyRokzZVPMOYHTh-QXk-41JfoUlZ715cP6FJUmVLeomu7Fxb3uF5j-qv5k04C3ZwDaOY4eks7Ww2ph8qnloafo_zPiFwuoqds</recordid><startdate>20180228</startdate><enddate>20180228</enddate><creator>Chen, C.</creator><creator>Wood, J.G.</creator><creator>Beutels, P.</creator><creator>Menzies, R.</creator><creator>MacIntyre, C.R.</creator><creator>Dirmesropian, S.</creator><creator>Reyes, J.F.</creator><creator>McIntyre, P.</creator><creator>Newall, A.T.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180228</creationdate><title>The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia</title><author>Chen, C. ; Wood, J.G. ; Beutels, P. ; Menzies, R. ; MacIntyre, C.R. ; Dirmesropian, S. ; Reyes, J.F. ; McIntyre, P. ; Newall, A.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-47ac801fa1038fc84d9badbad478cc2e3ab1bfe8f8299059df8479ba9ca504f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult vaccination</topic><topic>Adults</topic><topic>Age</topic><topic>Case reports</topic><topic>Children</topic><topic>Construction costs</topic><topic>Cost analysis</topic><topic>Disease</topic><topic>Economic evaluation</topic><topic>Elderly</topic><topic>Expenditures</topic><topic>Immunization</topic><topic>Influenza</topic><topic>Markov chains</topic><topic>Multi-cohort Markov modelling</topic><topic>Older people</topic><topic>PCV13</topic><topic>Pharmaceuticals</topic><topic>Pneumococcal</topic><topic>Pneumonia</topic><topic>Population</topic><topic>Quantitative analysis</topic><topic>Systematic review</topic><topic>Timeliness</topic><topic>Uptake</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, C.</creatorcontrib><creatorcontrib>Wood, J.G.</creatorcontrib><creatorcontrib>Beutels, P.</creatorcontrib><creatorcontrib>Menzies, R.</creatorcontrib><creatorcontrib>MacIntyre, C.R.</creatorcontrib><creatorcontrib>Dirmesropian, S.</creatorcontrib><creatorcontrib>Reyes, J.F.</creatorcontrib><creatorcontrib>McIntyre, P.</creatorcontrib><creatorcontrib>Newall, A.T.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library (ProQuest)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, C.</au><au>Wood, J.G.</au><au>Beutels, P.</au><au>Menzies, R.</au><au>MacIntyre, C.R.</au><au>Dirmesropian, S.</au><au>Reyes, J.F.</au><au>McIntyre, P.</au><au>Newall, A.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2018-02-28</date><risdate>2018</risdate><volume>36</volume><issue>10</issue><spage>1265</spage><epage>1271</epage><pages>1265-1271</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>While the impact of the timeliness of vaccine administration has been well-studied for childhood vaccinations, there has been little detailed quantitative analysis on the potential impact of the timeliness of vaccinations in older adults. The aim of this study was to explore the impact of implementing more realistic observed uptake distributions, taking into the account reduced vaccine efficacy but higher pneumococcal disease burden with increasing age beyond 65 years. A multi-cohort Markov model was constructed to evaluate the cost-effectiveness of a pneumococcal (PCV13) immunisation program in Australia, assuming two different uptake modelling approaches. The approach using an estimate of observed uptake was compared with a scenario in which the total cumulative uptake was delivered at the recommended age of vaccination. We found these two approaches produced different results both in terms of cases prevented and cost-effectiveness. The impact of the non-timely uptake in adult programs may sometimes have positive and other times negative effects, depending on several factors including the age-specific disease rates and the duration of vaccine protection. Our study highlights the importance of using realistic assumptions around uptake (including non-timely vaccination) when estimating the impact of vaccination in adults.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>29395534</pmid><doi>10.1016/j.vaccine.2018.01.052</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2018-02, Vol.36 (10), p.1265-1271 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1993993976 |
| source | Elsevier ScienceDirect Journals |
| subjects | Adult vaccination Adults Age Case reports Children Construction costs Cost analysis Disease Economic evaluation Elderly Expenditures Immunization Influenza Markov chains Multi-cohort Markov modelling Older people PCV13 Pharmaceuticals Pneumococcal Pneumonia Population Quantitative analysis Systematic review Timeliness Uptake Vaccination Vaccine efficacy Vaccines |
| title | The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A32%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20timeliness%20in%20the%20cost-effectiveness%20of%20older%20adult%20vaccination:%20A%20case%20study%20of%20pneumococcal%20conjugate%20vaccine%20in%20Australia&rft.jtitle=Vaccine&rft.au=Chen,%20C.&rft.date=2018-02-28&rft.volume=36&rft.issue=10&rft.spage=1265&rft.epage=1271&rft.pages=1265-1271&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2018.01.052&rft_dat=%3Cproquest_cross%3E2001526573%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2001526573&rft_id=info:pmid/29395534&rft_els_id=S0264410X18301014&rfr_iscdi=true |